A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: A study of five patients

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 3, 2007, Pages 384-387

  Brazzelli, V ^a   Prestinari, F ^a   Barbagallo, T ^a   Rona, C ^a   Orlandi, E ^a   Passamonti, F ^a   Locatelli, F ^a   Zecca, M ^a   Villani, S ^a   Borroni, G ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Chronic myeloid leukaemia; Colorimetry; Hypopigmentation; Imatinib mesylate

Indexed keywords

IMATINIB; STEM CELL FACTOR;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COLORIMETRY; DEPIGMENTATION; FEMALE; HUMAN; HYPOPIGMENTATION; LUMINANCE; MALE; MELANOCYTE; PATHOGENESIS; PRIORITY JOURNAL; SKIN COLOR;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; COLORIMETRY; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SKIN PIGMENTATION; STATISTICS, NONPARAMETRIC;

EID: 33847005917     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01981.x     Document Type: Article

References (28)

1. Peggs K, Mackinnon S. Imatinib Mesylate - the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003; 348: 1048-1050.
2. Faderl S, Talpaz M, Estrov Z et al. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164-172.
3. Sattler M, Griffin JD. Molecular mechanism of transformation by the BCR-ABL oncogene. Semin Hematol 2003: 40(s2): 4-10.
4. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 2001; 344: 1031-1037.
5. Druker BJ, Sawyers CL, Kantarjian H. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukaemia and acute lymphoblastic leukaemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
6. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med, 2002; 346: 683-693.
7. Grichnik JM, Burch JA, Burchette J, Shea CR. The SCF-KIT pathways plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 1998; 111: 233-238.
8. Valeyrie L, Bustuji-Garin S, Revuz J et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients. J Am Acad Dermatol 2003; 48: 201-206.
9. Breccia M, Carmosino I, Russo E et al. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 2005; 74: 121-123.
10. Brazzelli V, Prestinari F, Roveda E et al. Pityriasis rosea-like eruption during treatment with imatinib mesylate: Description of 3 cases. J Am Acad Dermatol, 2005; 53: S240-s243.
11. Raanani P, Goldman JM, Ben-Bassat I. Depigmentation in a chronic myeloid leukaemia patient treated with STI-571. J Clin Oncol 2002; 20: 869-870.
12. Hasan S, Dinh K, Lombardo F et al. Hypopigmentation in an African patient treated with imatinib mesylate: A case report. J Natl Med Assoc 2003; 95: 722-724.
13. Tsao AS, Kantarjian H, Cortes J et al. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003; 98: 2483-2487.
14. Rousselot P, Larghero J, Raffoux E et al. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate. Br J Haematol 2003; 120: 1091-1092.
15. Leong KW, Lee TC, Goh AS. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2004; 100: 2486-2488.
16. McPartlin S, Leach M. Loss of skin pigment caused by imatinib therapy. Br J Haematol 2005; 129: 448.
17. Brazzelli V, Roveda E, Prestinari F et al. Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: A non invasive colorimetric assessment. Pediatric Dermatol 2006; 23: 175-178.
18. Legros L, Cassuto JP, Ortonne JP. Imatinib mesylate (Glivec®): A systemic depigmenting agent for extensive vitiligo? Br J Dermatol 2005; 153: 691-692.
19. Park SB, Suh DH, Youn JI. A long term time course of colorimetric evaluation of ultraviolet light-induced skin reactions. Clin Exp Dermatol 1999; 24: 315-320.
20. Alaluf S, Atkins D, Barrett K et al. The impact of epidermal melanin on objective measurements of human skin colour. Pigment Cell Res 2002; 15: 119-126.
21. Chardon A, Cretois I, Hourseau C. Skin color typology and suntanning pathways. Int J Cosmet Sci 1991; 13: 191-208.
22. Fullerton A, Serup J. Site, gender and age variation in normal skin colour on the back and the forearm: Tristimulus colorimeter measurements. Skin Res Technol 1996; 2: 1-4.
23. Hermanns JF, Petit L, Hermanns-LêT, Piérard GE. Analytic quantification of phototype-related regional skin complexion. Skin Res Technol 2001; 7: 168-171.
24. Clarys P, Alewaeters K, Lambrecht R, Barel AO. Skin color measurements: comparison between three instruments: The Chromameter, the DermaSpectrometer and the Mexameter. Skin Res Technol 2000; 6: 230-238.
25. Andreassi L, Flori L. Practical applications of cutaneous colorimetry. Clin Dermatol 1995; 13: 369-373.
26. Fleischman RA. Human piebald trait resulting from a dominant negative mutant allele of the c-kit membrane receptor gene. J Clin Invest 1992; 89: 1713-1717.
27. Giebel LB, Spritz RA. Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. Proc Natl Acad Sci USA 1991; 88: 8696-8699.
28. Capdeville R, Silberman S. Imatinib: A targeted clinical drug development. Semin Hematol 2003; 40 (s2): 15-20.